Cita APA (7a ed.)

Conrad, P. W., Zacks, D. N., & Johnson, M. W. (2008). Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. Dove Medical Press.

Cita Chicago Style (17a ed.)

Conrad, P William, David N. Zacks, y Mark W. Johnson. Intravitreal Bevacizumab Has Initial Clinical Benefit Lasting Eight Weeks in Eyes with Neovascular Age-related Macular Degeneration. Dove Medical Press, 2008.

Cita MLA (8a ed.)

Conrad, P William, et al. Intravitreal Bevacizumab Has Initial Clinical Benefit Lasting Eight Weeks in Eyes with Neovascular Age-related Macular Degeneration. Dove Medical Press, 2008.